

# Given Names Deactivated Family Name

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255058/publications.pdf>

Version: 2024-02-01

319  
papers

18,255  
citations

23500

58  
h-index

19136

118  
g-index

346  
all docs

346  
docs citations

346  
times ranked

22219  
citing authors

#	ARTICLE	IF	CITATIONS
1	Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort. <i>Psychological Medicine</i> , 2023, 53, 66-77.	2.7	8
2	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. <i>Psychological Medicine</i> , 2023, 53, 1891-1905.	2.7	3
3	Metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort. <i>Revista De Psiquiatría Y Salud Mental</i> , 2023, 16, 175-183.	1.0	1
4	Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort. <i>Psychological Medicine</i> , 2022, 52, 770-779.	2.7	5
5	Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 5-15.	1.8	19
6	Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. <i>Pharmacopsychiatry</i> , 2022, 55, 40-47.	1.7	11
7	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. <i>Revista De Psiquiatría Y Salud Mental</i> , 2022, 15, 117-133.	1.0	2
8	A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium. <i>Human Brain Mapping</i> , 2022, 43, 352-372.	1.9	39
9	Routine cerebrospinal fluid parameters as biomarkers in first-episode psychosis: A prospective observational study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 112, 110424.	2.5	13
10	Examining the relationship between psychosis and immigration in Spain: The effect of cannabis use and language barrier in a large psychosis sample. <i>Journal of Psychiatric Research</i> , 2022, 145, 361-365.	1.5	1
11	Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes. <i>Medical Image Analysis</i> , 2022, 75, 102304.	7.0	28
12	Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain. <i>Psychiatry Research</i> , 2022, 308, 114352.	1.7	4
13	Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study. <i>Journal of Affective Disorders</i> , 2022, 300, 99-108.	2.0	3
14	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	6.0	44
15	Trauma and stressor-related disorders among health care workers during COVID-19 pandemic and the role of the gender: A prospective longitudinal survey. <i>Journal of Affective Disorders</i> , 2022, 302, 110-122.	2.0	14
16	Disentangling early and late onset of psychosis in women: identifying new targets for treatment. <i>Archives of Women's Mental Health</i> , 2022, 25, 335-344.	1.2	3
17	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. <i>Biological Psychiatry</i> , 2022, 92, 299-313.	0.7	11
18	A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research. <i>Schizophrenia Research</i> , 2022, 243, 467-469.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 215-226.	2.2	7
20	Reelin Alterations, Behavioral Phenotypes, and Brain Anomalies in Schizophrenia: A Systematic Review of Insights From Rodent Models. <i>Frontiers in Neuroanatomy</i> , 2022, 16, 844737.	0.9	8
21	Genetic variants associated with longitudinal changes in brain structure across the lifespan. <i>Nature Neuroscience</i> , 2022, 25, 421-432.	7.1	75
22	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 37-49.	2.0	4
23	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
24	Toward Understanding of Suicidality in a Spanish Clinical Population: Validation of the European Spanish Version of the Interpersonal Needs Questionnaire. <i>Psychopathology</i> , 2022, 55, 16-27.	1.1	0
25	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	1.3	1
26	Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis. <i>Schizophrenia Research</i> , 2022, 244, 71-80.	1.1	1
27	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 795-806.	1.0	5
28	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. <i>Schizophrenia Research</i> , 2022, 246, 30-38.	1.1	3
29	Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2022, 15, 117-133.	0.2	0
30	A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. <i>CNS Drugs</i> , 2022, 36, 659-679.	2.7	38
31	Epigenome-wide meta-analysis of blood DNA methylation and its association with subcortical volumes: findings from the ENIGMA Epigenetics Working Group. <i>Molecular Psychiatry</i> , 2021, 26, 3884-3895.	4.1	34
32	Entire duration of active psychosis and neurocognitive performance in first-episode non-affective psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 1266-1275.	0.9	0
33	Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study. <i>Molecular Psychiatry</i> , 2021, 26, 5307-5319.	4.1	18
34	Glossary on atmospheric electricity and its effects on biology. <i>International Journal of Biometeorology</i> , 2021, 65, 5-29.	1.3	9
35	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 673-682.	2.0	15
36	Long term cortical thickness changes after a first episode of non-affective psychosis: The 10-year follow-up of the PAFIP cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110180.	2.5	8

#	ARTICLE	IF	CITATIONS
37	The burden of disease in early schizophrenia – a systematic literature review. <i>Current Medical Research and Opinion</i> , 2021, 37, 109-121.	0.9	34
38	A network analysis approach to functioning problems in first psychotic episodes and their relationship with duration of untreated illness: Findings from the PAFIP cohort. <i>Journal of Psychiatric Research</i> , 2021, 136, 483-491.	1.5	3
39	COVID-19 Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time for Collaborative Research. <i>Biological Psychiatry</i> , 2021, 89, e29-e30.	0.7	21
40	Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 1-7.	1.0	12
41	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	6.0	136
42	Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. <i>Psychological Medicine</i> , 2021, 51, 340-350.	2.7	23
43	Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. <i>Psychological Medicine</i> , 2021, 51, 264-277.	2.7	15
44	COVID-19 una oportunidad única para explorar la relación entre la infección prenatal materna, el desarrollo cerebral y los trastornos neuropsiquiátricos en la descendencia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, 14, 1-3.	1.0	6
45	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. <i>Journal of Psychiatric Research</i> , 2021, 134, 150-157.	1.5	7
46	Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 646701.	1.6	24
47	Prognostic significance of psychotic relapse in patients with first-episode acute and transient psychosis: New empirical support for ICD-11. <i>Journal of Psychiatric Research</i> , 2021, 137, 486-490.	1.5	5
48	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. <i>European Neuropsychopharmacology</i> , 2021, 47, 74-85.	0.3	7
49	In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 535-568.	2.9	30
50	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8133.	1.2	7
51	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, 14, 157-163.	1.0	9
52	Predictive value of prolactin in first episode psychosis at ten years follow-up. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, 14, 179-180.	1.0	1
53	Stability of schizophrenia diagnosis in a 10-year longitudinal study on first episode of non-affective psychosis: Conclusions from the PAFIP cohort. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 342-357.	2.2	1
54	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2021, 14, 157-163.	0.2	4

#	ARTICLE	IF	CITATIONS
55	Predictive value of prolactin in first episode psychosis at ten years follow-up. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 179-180.	0.2	0
56	Prolactin, metabolic and immune parameters in na�ve subjects with a first episode of psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110332.	2.5	6
57	Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110309.	2.5	1
58	Metabolic syndrome in antipsychotic-na�ve patients with first-episode psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2307-2320.	2.7	24
59	Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3�year longitudinal study. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 578-588.	2.2	4
60	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. <i>Journal of Affective Disorders</i> , 2021, 295, 173-182.	2.0	32
61	COVID-19 una oportunidad �nica para explorar la relaci�n entre la infecci�n prenatal materna, el desarrollo cerebral y los trastornos neuropsiqui�tricos en la descendencia. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 1-3.	0.2	0
62	Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. <i>Psychopharmacology</i> , 2021, 238, 329-340.	1.5	42
63	Understanding the Influence of Personality Traits on Risk of Suicidal Behaviour in Schizophrenia Spectrum Disorders: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4604.	1.0	1
64	BOLD Coupling between Lesioned and Healthy Brain Is Associated with Glioma Patients� Recovery. <i>Cancers</i> , 2021, 13, 5008.	1.7	8
65	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. <i>Molecular Psychiatry</i> , 2020, 25, 584-602.	4.1	49
66	Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence. <i>Schizophrenia Bulletin</i> , 2020, 46, 17-26.	2.3	76
67	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. <i>Molecular Psychiatry</i> , 2020, 25, 2355-2372.	4.1	22
68	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies� PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	2.3	56
69	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. <i>JAMA Psychiatry</i> , 2020, 77, 420.	6.0	54
70	M167. MACHINE LEARNING CLASSIFICATION OF FIRST-EPISODE PSYCHOSIS USING CORTICAL THICKNESS IN A LARGE MULTICENTER MRI STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S200-S200.	2.3	0
71	S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. <i>Schizophrenia Bulletin</i> , 2020, 46, S72-S73.	2.3	2
72	Needs of people with psychosis and their caregivers: �en their own voice�. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2020, 13, 80-89.	0.2	5

#	ARTICLE	IF	CITATIONS
73	A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2020, 39, 46-55.	0.3	19
74	Data of a meta-analysis on pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia. <i>Data in Brief</i> , 2020, 31, 105904.	0.5	5
75	Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. <i>Clinical Drug Investigation</i> , 2020, 40, 861-871.	1.1	2
76	Grip Strength, Neurocognition, and Social Functioning in People With Type-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia. <i>Frontiers in Psychology</i> , 2020, 11, 525231.	1.1	9
77	Understanding sex differences in long-term outcomes after a first episode of psychosis. <i>NPJ Schizophrenia</i> , 2020, 6, 33.	2.0	36
78	Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6106.	1.8	6
79	Mental health and the SARS-CoV-2 pandemic. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2020, 13, 55-56.	0.2	0
80	M97. PREDICTORS OF TRANSITION TO SCHIZOPHRENIA IN BRIEF PSYCHOTIC DISORDER: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT. <i>Schizophrenia Bulletin</i> , 2020, 46, S171-S172.	2.3	0
81	Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, 13, 90-94.	1.0	117
82	Childhood trauma and substance use underlying psychosis: a systematic review. <i>Hägre Utbildning</i> , 2020, 11, 1748342.	1.4	17
83	Mental health and the SARS-CoV-2 pandemic. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, 13, 55-56.	1.0	19
84	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. <i>Data in Brief</i> , 2020, 30, 105599.	0.5	0
85	Breve salutaci3n y visi3n compartida. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, 13, 53-54.	1.0	0
86	Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 916-940.	0.4	3
87	Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2020, 222, 88-96.	1.1	29
88	The genetic architecture of the human cerebral cortex. <i>Science</i> , 2020, 367, .	6.0	450
89	Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners. <i>NeuroImage</i> , 2020, 220, 117127.	2.1	48
90	Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning. <i>Brain</i> , 2020, 143, 1027-1038.	3.7	158

#	ARTICLE	IF	CITATIONS
91	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 217-229.	1.0	40
92	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. <i>Schizophrenia Research</i> , 2020, 220, 240-247.	1.1	11
93	Brain grey matter abnormalities in first episode non-affective psychosis patients with suicidal behaviours: The role of neurocognitive functioning. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109948.	2.5	14
94	Necesidades de las personas con psicosis y sus cuidadores: Â«en voz propiaÂ». <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2020, 13, 80-89.	1.0	5
95	Prevalence of hepatitis C in patients with non-affective psychotic disorders. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 550-554.	0.1	8
96	Suicidal Behavior and Personality Traits Contribute to Disability in Firstâ€¦Episode Psychosis: A 1â€¦Year Followâ€¦up Study. <i>Suicide and Life-Threatening Behavior</i> , 2019, 49, 798-810.	0.9	9
97	AntipsicÃ³ticos inyectables de liberaciÃ³n prolongada para el tratamiento de la esquizofrenia en EspaÃ±a. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2019, 12, 92-105.	1.0	23
98	Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients. <i>Archives of Women's Mental Health</i> , 2019, 22, 367-373.	1.2	22
99	Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study.. <i>Journal of Affective Disorders</i> , 2019, 257, 31-37.	2.0	12
100	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2019, 12, 92-105.	0.2	3
101	S68. UNALTERED FRONTAL AND PREFRONTAL BRAIN RESPONSE DURING WORK MEMORY TASKS IN PATIENTS WITH A FIRST EPISODE PSYCHOSIS META-ANALYSIS STUDY. <i>Schizophrenia Bulletin</i> , 2019, 45, S332-S333.	2.3	0
102	Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. <i>Journal of Psychopharmacology</i> , 2019, 33, 284-294.	2.0	18
103	10Kin1day: A Bottom-Up Neuroimaging Initiative. <i>Frontiers in Neurology</i> , 2019, 10, 425.	1.1	15
104	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. <i>Science Advances</i> , 2019, 5, eaau9093.	4.7	22
105	Longitudinal studies of functional magnetic resonance imaging in first-episode psychosis: A systematic review. <i>European Psychiatry</i> , 2019, 59, 60-69.	0.1	24
106	Time dependent expression of the blood biomarkers EIF2D and TOX in patients with schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 909-915.	2.0	3
107	Sex differences in gene expression related to antipsychotic induced weight gain. <i>PLoS ONE</i> , 2019, 14, e0215477.	1.1	13
108	Altered gene expression in antipsychotic-induced weight gain. <i>NPJ Schizophrenia</i> , 2019, 5, 7.	2.0	16

#	ARTICLE	IF	CITATIONS
109	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019, 12, 1-8.	0.2	5
110	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. <i>JAMA Psychiatry</i> , 2019, 76, 864.	6.0	43
111	Patterns of recovery course in early intervention for FIRST episode non-affective psychosis patients: The role of timing. <i>Schizophrenia Research</i> , 2019, 209, 245-254.	1.1	4
112	Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. <i>Translational Psychiatry</i> , 2019, 9, 306.	2.4	16
113	Multimodal Integration of Brain Images for MRI-Based Diagnosis in Schizophrenia. <i>Frontiers in Neuroscience</i> , 2019, 13, 1203.	1.4	26
114	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , 2019, 51, 1624-1636.	9.4	192
115	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	4.0	127
116	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	0.7	5
117	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019, 12, 1-8.	1.0	68
118	Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention. <i>Microbial Biotechnology</i> , 2019, 13, 1182-1190.	0.9	11
119	Insight and risk of suicidal behaviour in two first-episode psychosis cohorts: Effects of previous suicide attempts and depression. <i>Schizophrenia Research</i> , 2019, 204, 80-89.	1.1	28
120	Verbal memory and voxel based morphometry in first episode non-affective psychosis: A process oriented approach.. <i>Neuropsychology</i> , 2019, 33, 568-580.	1.0	1
121	Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review. <i>Psychiatry Investigation</i> , 2019, 16, 336-345.	0.7	22
122	Targeting recovery in first episode psychosis: The importance of neurocognition and premorbid adjustment in a 3-year longitudinal study. <i>Schizophrenia Research</i> , 2018, 195, 320-326.	1.1	18
123	Premorbid IQ subgroups in first episode non affective psychosis patients: Long-term sex differences in function and neurocognition. <i>Schizophrenia Research</i> , 2018, 197, 370-377.	1.1	26
124	The effect of excess weight on circulating inflammatory cytokines in drug-naïve first-episode psychosis individuals. <i>Journal of Neuroinflammation</i> , 2018, 15, 63.	3.1	19
125	F81. AGE OF ONSET OF CANNABIS USE AND COGNITIVE FUNCTION IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS PATIENTS: 3-YEAR FOLLOW-UP OUTCOME. <i>Schizophrenia Bulletin</i> , 2018, 44, S251-S251.	2.3	0
126	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. <i>European Psychiatry</i> , 2018, 52, 29-37.	0.1	17



#	ARTICLE	IF	CITATIONS
127	Tobacco smoking and its association with cognition in first episode psychosis patients. <i>Schizophrenia Research</i> , 2018, 192, 269-273.	1.1	34
128	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. <i>Psychopharmacology</i> , 2018, 235, 245-255.	1.5	30
129	A polygenic risk score analysis of psychosis endophenotypes across brain functional, structural, and cognitive domains. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 21-34.	1.1	57
130	Low-density lipoprotein cholesterol and suicidal behaviour in a large sample of first-episode psychosis patients. <i>World Journal of Biological Psychiatry</i> , 2018, 19, S158-S161.	1.3	17
131	O6.7. COMMON NEUROANATOMICAL ABNORMALITIES IN FIRST EPISODE PSYCHOSIS ACROSS SEVERAL INDEPENDENT SAMPLES. <i>Schizophrenia Bulletin</i> , 2018, 44, S92-S92.	2.3	0
132	T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S184-S184.	2.3	0
133	F124. SEX DIFFERENCES IN OUTCOME IN FIRST EPISODE PSYCHOSIS PATIENTS: A 10-YEAR FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S268-S268.	2.3	0
134	S124. RECOVERY TRAJECTORIES IN FIRST EPISODE PSYCHOSIS PATIENTS: THE ROLE OF TIMING. <i>Schizophrenia Bulletin</i> , 2018, 44, S373-S373.	2.3	0
135	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , 2018, 9, 30869-30882.	0.8	9
136	S125. THE DYNAMIC RELATIONSHIP BETWEEN INSIGHT AND SUICIDAL BEHAVIOUR IN FIRST EPISODE PSYCHOSIS PATIENTS OVER 3-YEAR FOLLOW-UP. <i>Schizophrenia Bulletin</i> , 2018, 44, S374-S374.	2.3	2
137	Diverse definitions of the early course of schizophrenia—a targeted literature review. <i>NPJ Schizophrenia</i> , 2018, 4, 21.	2.0	52
138	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1090-1101.	1.0	16
139	Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders. <i>Biochemical Pharmacology</i> , 2018, 157, 258-265.	2.0	15
140	Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up. <i>Schizophrenia Research</i> , 2018, 201, 159-166.	1.1	6
141	F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S259-S259.	2.3	0
142	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> , 2018, 84, 644-654.	0.7	627
143	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018, 113, 1639-1648.	0.2	72
144	Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals: A 36-months randomized study. <i>Schizophrenia Research</i> , 2018, 202, 226-233.	1.1	37

#	ARTICLE	IF	CITATIONS
145	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	6.0	1,085
146	Blood Gene Expression Profile Predicts Response to Antipsychotics. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 73.	1.4	18
147	Gain-of-function mutations in DNMT3A in patients with paraganglioma. <i>Genetics in Medicine</i> , 2018, 20, 1644-1651.	1.1	73
148	Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. <i>British Journal of Psychiatry</i> , 2018, 213, 535-541.	1.7	37
149	S173. GREY MATTER VOLUME DEFFICITS IN PATIENTS WITH A FIRST EPISODE NON-AFFECTIVE PSYCHOSIS AND SUICIDE RELATED BEHAVIOUR. <i>Schizophrenia Bulletin</i> , 2018, 44, S392-S392.	2.3	0
150	The dynamic relationship between insight and suicidal behavior in first episode psychosis patients over 3-year follow-up. <i>European Neuropsychopharmacology</i> , 2018, 28, 1161-1172.	0.3	20
151	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. <i>Cell</i> , 2018, 173, 1705-1715.e16.	13.5	623
152	The right occipital lobe and poor insight in first-episode psychosis. <i>PLoS ONE</i> , 2018, 13, e0197715.	1.1	16
153	T72. VERBAL MEMORY AND VOXEL BASED MORPHOMETRY IN FIRST EPISODE NON-AFFECTIVE PSYCHOSIS: A PROCESS ORIENTED APPROACH. <i>Schizophrenia Bulletin</i> , 2018, 44, S142-S142.	2.3	0
154	Novel genetic loci associated with hippocampal volume. <i>Nature Communications</i> , 2017, 8, 13624.	5.8	250
155	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
156	Disability multilevel modelling in first episodes of psychosis at 3-year follow-up. <i>Schizophrenia Research</i> , 2017, 185, 101-106.	1.1	3
157	Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. <i>Schizophrenia Research</i> , 2017, 189, 134-141.	1.1	20
158	Validation of schizophrenia gene expression profile in a preclinical model of maternal infection during pregnancy. <i>Schizophrenia Research</i> , 2017, 189, 217-218.	1.1	1
159	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. <i>Psychopharmacology</i> , 2017, 234, 2563-2570.	1.5	27
160	Cuando la asistencia no sigue a la evidencia: el caso de la falta de programas de intervenci3n temprana en psicosis en EspaA±a. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 78-86.	1.0	37
161	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
162	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. <i>Systematic Reviews</i> , 2017, 6, 69.	2.5	24

#	ARTICLE	IF	CITATIONS
163	Enhanced Stress Response in 5-HT <sub>1A</sub> Overexpressing Mice: Altered HPA Function and Hippocampal Long-Term Potentiation. ACS Chemical Neuroscience, 2017, 8, 2393-2401.	1.7	10
164	Longitudinal investigation of the parietal lobe anatomy in bipolar disorder and its association with general functioning. Psychiatry Research - Neuroimaging, 2017, 267, 22-31.	0.9	17
165	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 315-323.	1.8	32
166	Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Brain Imaging and Behavior, 2017, 11, 1497-1514.	1.1	144
167	The effects of tobacco smoking on age of onset of psychosis and psychotic symptoms in a first-episode psychosis population. Addiction, 2017, 112, 526-532.	1.7	8
168	Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients. NeuroImage, 2017, 145, 246-253.	2.1	43
169	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838
170	Common and distinct structural features of schizophrenia and bipolar disorder: The European Network on Psychosis, Affective disorders and Cognitive Trajectory (ENPACT) study. PLoS ONE, 2017, 12, e0188000.	1.1	74
171	Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. PLoS ONE, 2017, 12, e0183613.	1.1	12
172	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. Lecture Notes in Computer Science, 2017, 10541, 371-378.	1.0	4
173	Evidence for Trait Related Theory of Mind Impairment in First Episode Psychosis Patients and Its Relationship with Processing Speed: A 3 Year Follow-up Study. Frontiers in Psychology, 2016, 7, 592.	1.1	21
174	Counterfactual Reasoning in Non-psychotic First-Degree Relatives of People with Schizophrenia. Frontiers in Psychology, 2016, 7, 665.	1.1	7
175	Environmental factors linked to depression vulnerability are associated with altered cerebellar resting-state synchronization. Scientific Reports, 2016, 6, 37384.	1.6	21
176	Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Revista De Psiquiatría Y Salud Mental (English Edition), 2016, 9, 158-173.	0.2	23
177	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
178	Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurology and Therapy, 2016, 5, 105-130.	1.4	22
179	Homocysteine and cognition: A systematic review of 111 studies. Neuroscience and Biobehavioral Reviews, 2016, 69, 280-298.	2.9	51
180	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, 233, 3947-3952.	1.5	40

#	ARTICLE	IF	CITATIONS
181	Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 619-628.	1.8	28
182	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv132.	1.0	50
183	Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. <i>JAMA Psychiatry</i> , 2016, 73, 497.	6.0	51
184	Towards a blood-based diagnostic panel for bipolar disorder. <i>Brain, Behavior, and Immunity</i> , 2016, 52, 49-57.	2.0	59
185	Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 158-173.	1.0	47
186	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHG). <i>Maturitas</i> , 2016, 83, 83-93.	1.0	39
187	Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis. <i>Brain Imaging and Behavior</i> , 2016, 10, 629-635.	1.1	6
188	Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 492-500.	1.1	47
189	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	4.0	150
190	Grey matter volume differences in non-affective psychosis and the effects of age of onset on grey matter volumes: A voxelwise study. <i>Schizophrenia Research</i> , 2015, 164, 74-82.	1.1	26
191	Disability in bipolar I disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0. <i>Journal of Affective Disorders</i> , 2015, 174, 353-360.	2.0	35
192	Season of birth and subclinical psychosis: Systematic review and meta-analysis of new and existing data. <i>Psychiatry Research</i> , 2015, 225, 227-235.	1.7	8
193	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , 2015, 520, 224-229.	13.7	772
194	Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	37
195	Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 112-119.	0.9	34
196	Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. <i>Frontiers in Physiology</i> , 2015, 6, 108.	1.3	35
197	Inpatient Treatment for Anorexia Nervosa. <i>Journal of Psychiatric Practice</i> , 2015, 21, 49-59.	0.3	19
198	Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. <i>Neuropsychobiology</i> , 2015, 71, 103-111.	0.9	9

#	ARTICLE	IF	CITATIONS
199	Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors. <i>European Neuropsychopharmacology</i> , 2015, 25, 2278-2288.	0.3	58
200	Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 144-156.	0.7	17
201	A cross-sectional and longitudinal structural magnetic resonance imaging study of the post-central gyrus in first-episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 42-49.	0.9	16
202	Birth Weight and Adult IQ, but Not Anxious-Depressive Psychopathology, Are Associated with Cortical Surface Area: A Study in Twins. <i>PLoS ONE</i> , 2015, 10, e0129616.	1.1	6
203	Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review. <i>Current Neuropharmacology</i> , 2015, 13, 422-434.	1.4	39
204	Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection. <i>Neuroepidemiology</i> , 2014, 42, 121-122.	1.1	23
205	Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 41-51.	1.0	94
206	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 89-105.	4.0	164
207	Clinical Spanish Norms of the Stroop Test for Traumatic Brain Injury and Schizophrenia. <i>Spanish Journal of Psychology</i> , 2014, 17, E96.	1.1	6
208	Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. <i>Psychopharmacology</i> , 2014, 231, 357-366.	1.5	21
209	Immune system: A possible nexus between cannabinoids and psychosis. <i>Brain, Behavior, and Immunity</i> , 2014, 40, 269-282.	2.0	47
210	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. <i>Brain Imaging and Behavior</i> , 2014, 8, 153-182.	1.1	696
211	Lack of insight 3 years after first-episode psychosis: An unchangeable illness trait determined from first presentation?. <i>Schizophrenia Research</i> , 2014, 157, 271-277.	1.1	21
212	Differential associations of cognitive insight components with pretreatment characteristics in first-episode psychosis. <i>Psychiatry Research</i> , 2014, 215, 308-313.	1.7	13
213	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. <i>Schizophrenia Research</i> , 2014, 159, 90-94.	1.1	34
214	A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation. <i>Biological Psychiatry</i> , 2014, 75, 386-397.	0.7	44
215	No sex differences in neuropsychological performance in first episode psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 149-154.	2.5	47
216	A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis. <i>Psychiatry Investigation</i> , 2014, 11, 186.	0.7	16

#	ARTICLE	IF	CITATIONS
217	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. <i>BMC Psychiatry</i> , 2013, 13, 127.	1.1	37
218	Genome-wide association analysis identifies 13 new risk loci for schizophrenia. <i>Nature Genetics</i> , 2013, 45, 1150-1159.	9.4	1,395
219	Course of cognitive deficits in first episode of non-affective psychosis: A 3-year follow-up study. <i>Schizophrenia Research</i> , 2013, 150, 121-128.	1.1	34
220	Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 162-167.	2.5	35
221	BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: A 3year follow-up study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 201-206.	2.5	6
222	Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. <i>Psychiatry Research</i> , 2013, 206, 181-187.	1.7	33
223	Predictors of neurocognitive impairment at 3years after a first episode non-affective psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 23-28.	2.5	18
224	Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial. <i>Schizophrenia Research</i> , 2013, 147, 375-382.	1.1	21
225	The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study. <i>Psychiatry Research</i> , 2013, 209, 302-308.	1.7	54
226	Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. <i>Psychopharmacology</i> , 2013, 227, 615-625.	1.5	23
227	Aripiprazole, Ziprasidone, and Quetiapine in the Treatment of First-Episode Nonaffective Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 215-220.	0.7	20
228	Neuroanatomical Differences between First-Episode Psychosis Patients with and without Neurocognitive Deficit: A 3-Year Longitudinal Study. <i>Frontiers in Psychiatry</i> , 2013, 4, 134.	1.3	9
229	Chapter 10 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients., 2013, , 107-113.		0
230	Long-Term Effect of Haloperidol, Olanzapine, and Risperidone on Plasma Prolactin Levels in Patients With First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 804-808.	0.7	24
231	White Matter Abnormalities in Veterans With Mild Traumatic Brain Injury. <i>American Journal of Psychiatry</i> , 2012, 169, 1284-1291.	4.0	136
232	Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5024-5035.	0.9	48
233	Homocysteine and cognition in first-episode psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 557-564.	1.8	51
234	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. <i>Journal of Psychiatric Research</i> , 2012, 46, 1099-1105.	1.5	118

#	ARTICLE	IF	CITATIONS
235	Identifying attentional deficits in people with first-episode psychosis with the Scale for the Assessment of Negative Symptoms attention subscale: is it possible?. <i>Comprehensive Psychiatry</i> , 2012, 53, 701-705.	1.5	5
236	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 240-247.	1.1	56
237	Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. <i>Schizophrenia Research</i> , 2012, 141, 22-28.	1.1	28
238	One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 80-83.	0.9	9
239	Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. <i>Psychopharmacology</i> , 2012, 219, 225-233.	1.5	24
240	Chapter 9 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2012, , 103-109.		1
241	A Digit Symbol Coding Task as a Screening Instrument for Cognitive Impairment in First-Episode Psychosis. <i>Archives of Clinical Neuropsychology</i> , 2011, 26, 48-58.	0.3	48
242	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011, 130, 137-142.	1.1	44
243	Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naïve first-episode psychosis patients. <i>Schizophrenia Research</i> , 2011, 131, 82-89.	1.1	7
244	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 84-90.	2.5	4
245	Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: The effect on cognitive functioning. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 616-623.	2.5	19
246	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. <i>Psychiatry Research</i> , 2011, 185, 286-289.	1.7	23
247	No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. <i>Lancet Oncology</i> , The, 2011, 12, 604-608.	5.1	122
248	Insight dimensions in first-episode psychosis patients: clinical, cognitive, pre-morbid and socio-demographic correlates. <i>Microbial Biotechnology</i> , 2011, 5, 140-149.	0.9	31
249	Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. <i>Journal of Psychiatric Research</i> , 2011, 45, 763-769.	1.5	21
250	Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. <i>Journal of Psychopharmacology</i> , 2011, 25, 744-754.	2.0	15
251	Effects of Family Psychoeducation on Expressed Emotion and Burden of Care in First-Episode Psychosis: A Prospective Observational Study. <i>Spanish Journal of Psychology</i> , 2010, 13, 389-395.	1.1	32
252	Effect of FTO, SH2B1, LEP, and LEPR Polymorphisms on Weight Gain Associated With Antipsychotic Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 661-666.	0.7	44

#	ARTICLE	IF	CITATIONS
253	Insular cortex morphometry in first-episode schizophrenia-spectrum patients: Diagnostic specificity and clinical correlations. <i>Journal of Psychiatric Research</i> , 2010, 44, 314-320.	1.5	22
254	Insular cortex thinning in first episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 216-222.	0.9	25
255	Temporal pole morphology in first-episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2010, 184, 189-191.	0.9	8
256	Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. <i>Brain Research</i> , 2010, 1317, 297-304.	1.1	71
257	White Matter Integrity and Cognitive Impairment in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2010, 167, 451-458.	4.0	131
258	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , 2010, 116, 243-251.	1.1	55
259	Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. <i>Schizophrenia Research</i> , 2010, 116, 16-19.	1.1	56
260	First-episode schizophrenia patients neuropsychologically within the normal limits: Evidence of deterioration in speed of processing. <i>Schizophrenia Research</i> , 2010, 119, 18-26.	1.1	34
261	Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. <i>Schizophrenia Research</i> , 2010, 121, 207-212.	1.1	37
262	Cannabis use and cognitive functioning in first-episode schizophrenia patients. <i>Schizophrenia Research</i> , 2010, 124, 142-151.	1.1	52
263	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 189-194.	1.7	29
264	Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: Clinical-onset implications. <i>Psychiatry Research</i> , 2010, 179, 291-296.	1.7	46
265	White matter defects in first episode psychosis patients: A voxelwise analysis of diffusion tensor imaging. <i>NeuroImage</i> , 2010, 49, 199-204.	2.1	92
266	Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. <i>NeuroImage</i> , 2010, 53, 1016-1022.	2.1	41
267	Longitudinal course of cognition in schizophrenia. <i>British Journal of Psychiatry</i> , 2009, 195, 84-84.	1.7	2
268	Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia. <i>Evidence-Based Mental Health</i> , 2009, 12, 55-55.	2.2	0
269	Assessment of the increase in variability when combining volumetric data from different scanners. <i>Human Brain Mapping</i> , 2009, 30, 355-368.	1.9	48
270	A Neuregulin 1 Variant Is Associated with Increased Lateral Ventricle Volume in Patients with First-Episode Schizophrenia. <i>Biological Psychiatry</i> , 2009, 65, 535-540.	0.7	54



#	ARTICLE	IF	CITATIONS
271	Glucose and lipid disturbances after 1Âyear of antipsychotic treatment in a drug-naÃve population. Schizophrenia Research, 2009, 107, 115-121.	1.1	83
272	Specific brain structural abnormalities in first-episode schizophrenia.. Schizophrenia Research, 2009, 115, 191-201.	1.1	32
273	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health and Quality of Life Outcomes, 2009, 7, 28.	1.0	37
274	Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis. Journal of Clinical Psychiatry, 2009, 70, 717-729.	1.1	58
275	Cognitive functioning and negative symptoms in first episode schizophrenia: Different patterns of correlates. Neurotoxicity Research, 2008, 14, 227-235.	1.3	13
276	Treatment of the first episode of schizophrenia: An update on pharmacologic and psychological interventions. Current Psychiatry Reports, 2008, 10, 202-209.	2.1	15
277	Catecholâ€methyltransferase <i>Val158Met</i> polymorphism and clinical characteristics in first episode nonâ€effective psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 550-556.	1.1	23
278	Epidemiological factors associated with treated incidence of firstâ€episode nonâ€effective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Microbial Biotechnology, 2008, 2, 178-187.	0.9	131
279	Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Research - Neuroimaging, 2008, 162, 167-171.	0.9	5
280	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophrenia Research, 2008, 99, 139-148.	1.1	78
281	Weight gain induced by haloperidol, risperidone and olanzapine after 1Âyear: Findings of a randomized clinical trial in a drug-naÃve population. Schizophrenia Research, 2008, 99, 13-22.	1.1	102
282	1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophrenia Research, 2008, 104, 165-174.	1.1	42
283	Interleukin-12 plasma levels in drug-naÃve patients with a first episode of psychosis: Effects of antipsychotic drugs. Psychiatry Research, 2008, 158, 206-216.	1.7	49
284	Effect of antipsychotic drugs on brain morphometry.. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1936-1943.	2.5	46
285	Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis. Schizophrenia Research, 2008, 102, 206-209.	1.1	15
286	Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. CNS Drugs, 2008, 22, 547-562.	2.7	229
287	Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment. Journal of Clinical Psychopharmacology, 2008, 28, 289-295.	0.7	74
288	Preserved Orbitofrontal Function in First-Episode Schizophrenia. Journal of Nervous and Mental Disease, 2008, 196, 67-70.	0.5	4

#	ARTICLE	IF	CITATIONS
289	Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment. <i>Canadian Journal of Psychiatry</i> , 2008, 53, 839-47.	0.9	11
290	Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. <i>British Journal of Psychiatry</i> , 2007, 191, s107-s110.	1.7	108
291	Neuropsychological functioning and brain structure in schizophrenia. <i>International Review of Psychiatry</i> , 2007, 19, 325-336.	1.4	62
292	Low-activity allele of Catechol-O-Methyltransferase (COMT) is associated with increased lateral ventricles in patients with first episode non-affective psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1514-1518.	2.5	17
293	Reduced thalamic volume in first-episode non-affective psychosis: Correlations with clinical variables, symptomatology and cognitive functioning. <i>NeuroImage</i> , 2007, 35, 1613-1623.	2.1	66
294	The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. <i>Schizophrenia Research</i> , 2007, 91, 226-237.	1.1	85
295	Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. <i>Schizophrenia Research</i> , 2007, 91, 87-96.	1.1	76
296	Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. <i>Journal of Psychiatric Research</i> , 2007, 41, 659-666.	1.5	87
297	Cognitive dimensions in first-episode schizophrenia spectrum disorders. <i>Journal of Psychiatric Research</i> , 2007, 41, 968-977.	1.5	77
298	A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naive, First-Episode Psychosis Patients Treated With Haloperidol, Olanzapine, or Risperidone. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1733-1740.	1.1	87
299	Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 364-371.	1.8	38
300	Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 939-943.	1.1	15
301	Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis Patients. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1253-1260.	1.1	152
302	A Practical Clinical Trial Comparing Haloperidol, Risperidone, and Olanzapine for the Acute Treatment of First-Episode Nonaffective Psychosis. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1511-1521.	1.1	138
303	Alcohol Misuse and Mood Disorders Following Traumatic Brain Injury. <i>Archives of General Psychiatry</i> , 2005, 62, 742.	13.8	116
304	Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: A dissociation between dorsolateral and orbitofrontal functioning. <i>Schizophrenia Research</i> , 2005, 77, 279-288.	1.1	79
305	Major Depression Following Traumatic Brain Injury. <i>Archives of General Psychiatry</i> , 2004, 61, 42.	13.8	637
306	Morphometry of the Superior Temporal Plane In Schizophrenia: Relationship to Clinical Correlates. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004, 16, 284-294.	0.9	26

#	ARTICLE	IF	CITATIONS
307	Temporal pole morphology and psychopathology in males with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2004, 132, 107-115.	0.9	43
308	Morphology of the lateral superior temporal gyrus in neuroleptic naïve patients with schizophrenia: relationship to symptoms. <i>Schizophrenia Research</i> , 2003, 60, 173-181.	1.1	52
309	Emotions in Unmedicated Patients With Schizophrenia During Evaluation With Positron Emission Tomography. <i>American Journal of Psychiatry</i> , 2003, 160, 1775-1783.	4.0	182
310	Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunction. <i>Biological Psychiatry</i> , 2002, 52, 1-8.	0.7	78
311	Sex differences in the absence of massa intermedia in patients with schizophrenia versus healthy controls. <i>Schizophrenia Research</i> , 2001, 48, 177-185.	1.1	46
312	Neural basis of novel and well-learned recognition memory in schizophrenia: A positron emission tomography study. <i>Human Brain Mapping</i> , 2001, 12, 219-231.	1.9	66
313	Neural Mechanisms of Anhedonia in Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 427.	3.8	214
314	Novel vs. Well-learned Memory for Faces: A Positron Emission Tomography Study. <i>Journal of Cognitive Neuroscience</i> , 2000, 12, 255-266.	1.1	39
315	Cerebral cortex: a topographic segmentation method using magnetic resonance imaging. <i>Psychiatry Research - Neuroimaging</i> , 2000, 100, 97-126.	0.9	66
316	An MRI-Based Parcellation Method for the Temporal Lobe. <i>NeuroImage</i> , 2000, 11, 271-288.	2.1	154
317	Regional frontal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study. <i>Biological Psychiatry</i> , 2000, 48, 110-119.	0.7	121
318	Regional cerebral blood flow in obsessive-compulsive patients with and without a chronic tic disorder. A SPECT study.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, 156-161.	1.8	42
319	Human Frontal Cortex: An MRI-Based Parcellation Method. <i>NeuroImage</i> , 1999, 10, 500-519.	2.1	122